Anti-CD3 mAbs may prolong beta cell function up to 2 years in patients with new onset Type 1 diabetes (T1DM). A randomized open label trial of anti-CD3 mAb, Teplizumab, in T1DM was stopped after 10 subjects because of increased adverse events than in a previous trial related with higher dosing of dr...
Bibliographische Detailangaben
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 132(2009), 2 vom: 26. Aug., Seite 166-73
|
|---|
| 1. Verfasser: |
Herold, Kevan C
(VerfasserIn) |
|---|
| Weitere Verfasser: |
Gitelman, Stephen,
Greenbaum, Carla,
Puck, Jennifer,
Hagopian, William,
Gottlieb, Peter,
Sayre, Peter,
Bianchine, Peter,
Wong, Emelita,
Seyfert-Margolis, Vicki,
Bourcier, Kasia,
Bluestone, Jeffrey A,
Immune Tolerance Network ITN007AI Study Group |
|---|
| Format: | Online-Aufsatz
|
|---|
| Sprache: | English |
|---|
| Veröffentlicht: |
2009
|
|---|
| Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.)
|
|---|
| Schlagworte: | Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Antibodies, Monoclonal, Humanized
C-Peptide
CD3 Complex
Hypoglycemic Agents
Insulin
Muromonab-CD3
mehr...
teplizumab
S4M959U2IJ |
|---|